Table 2.
Univariable analysis of factors associated with disease-free survival
| Chi2 | df | p value | |
|---|---|---|---|
| Gender | 0.446 | 1 | 0.504 |
| Age | 3.427 | 3 | 0.330 |
| Tumor histology | 0.164 | 1 | 0.686 |
| PET/CT | 3.964 | 1 | 0.046 |
| PET/CT scanner | 0.244 | 1 | 0.621 |
| Neoadjuvant therapy (all types) | 10.837 | 1 | 0.001 |
| Neoadjuvant chemoRx | 19.474 | 1 | < 0.0001 |
| Neoadjuvant CRTx | 0.684 | 1 | 0.408 |
| Surgery type* | 2.620 | 2 | 0.270 |
| pT stage | 390.092 | 5 | < 0.0001 |
| pN stage | 418.258 | 4 | < 0.0001 |
| R1 resection | 365.946 | 2 | < 0.0001 |
df degrees of freedom, Age < 50, 50–59, 60–79, > 70, PET/CT location, Cheltenham/Cardiff, Neoadjuvant therapy –all types, chemotherapy/chemo radiotherapy, Neoadjuvant chemoRx neoadjuvant chemotherapy, Neoadjuvant CRTx, neoadjuvant chemo radiotherapy, Surgery type *Trans hiatal esophagectomy/trans thoracic esophagectomy/3-stage esophagectomy, pT pathological T stage, pN pathological N stage, R1 positive resection margin